1 TC Sağlık Bakanlığı Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ...

103. Sharma T, Antonova L: Cognitive function in schizophrenia. Deficits, functional
consequences and future treatment. Psychiatr Clin North Am 2003; 26: 25–40.
104. Beverly MJ, Fisger R: A trial of compliance therapy in outpatients with schizophrenia or
schizoaffektive disorder. J Clin Psych 2005; 66: 997–1001.
105. Pitschel-Walz G, Bauml J,Bender W: Psycheducation and compliance in the treatment of
schizophrenia: results of the Munich Psychosis Information Project study. J Clin Psych 2006;
443–452.
106. Tel H, Terakye G: Şizofrenik hasta ailelerine yönelik bir psikoeğitimsel yaklaşım
uygulaması denemesi. Anadolu Psikiyetri Dergisi 2000; 1: 133–142.
107. Freudenrich O, Cather C, Evins AE: Attitudes of schizophrenia outpatients toward
psychiatric medications: relationship to clinical variables and insight. J Clin Psychiztr
2004;65: 1372–1376.
108. Farmer KC: Methods for measuring and monitoring medication regimen adherence in
clinical trials and clinical practice. Clin Ther 1999;21: 1074–1090.
109. Keith SJ, Kane JM: Partial compliance and patient consequences in schizophrenia: our
patients can do better. J Clin Psych 2003; 64: 1308–1315.
110. Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta
Psychiatr Scand Suppl 1994; 382: 28–32.
111. Valenstein M, Rorsch DS. Poor antipsychotic adherence among patients with
schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–264.
112. Sajatovic M, Blow FC. Insight into illness and attiyudes toward medications among
inpatients with schizophrenia. Psychiatry Serv 2002; 53: 1319–1321.
134